ConnectiCare

Commercial & HealthCare Exchange PA Criteria

Effective: June 3, 2020

Prior Authorization: Reyvow

Products Affected: Reyvow (lasmiditan) Tablets

Medication Description:
Reyvow is a first in its class that binds with high affinity and selectivity to the 5-HT1F receptor. The $5\text{-}HT_{1F}$ receptor subtype is located in the trigeminal ganglion, the trigeminal nucleus caudalis, and cephalic blood vessels. Selective targeting of the 5-HT1F receptor is hypothesized to decrease stimulation of the trigeminal system and treat migraine pain without causing vasoconstriction.

Covered Uses: Acute treatment of migraine with or without aura

Exclusion Criteria: N/A

Required Medical Information:
1. Diagnosis
2. Previous therapy regimen

Age Restrictions: 18 years of age or older

Prescriber Restrictions: N/A

Coverage Duration: 1 year

Other Criteria:
Migraine, Acute Treatment Approve if the patent meets all the following criteria:
- A. Patient has a diagnosis of migraine; **AND**
- B. Patient meets ONE of the following (i or ii**):**
  - i. Patient has tried at least TWO triptan therapies; **OR**
  - ii. Patient has a contraindication to triptan(s) according to the prescriber.

References:

1. Reyvow (lasmiditan) [prescribing information]. Indianapolis, IN: Lilly USA, LLC; October 2019.
2. Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 2019;20(1):37.
3. Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine. Neurology. 2018;91:e2222-e2232.
4. Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142:1894-1904.

Policy Revision history

ConnectiCare

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	06/03/20